Cookies help us deliver our services. By using our services, you agree to our use of cookies. More information

Dambrova 2022 BEC

From Bioblast

Bioblast2022 banner.jpg


Bioenergetics Communications        
Gnaiger 2020 BEC MitoPathways
       
Gnaiger Erich et al ― MitoEAGLE Task Group (2020) Mitochondrial physiology. Bioenerg Commun 2020.1.
        MitoPedia: BEC         MitoPedia: Gentle Science         MitoFit Preprints         DOI Data Center
Bioenergetics Communications
Publications in the MiPMap
Dambrova M, Cecatto C, Vilskersts R, Liepinsh E (2022) Mitochondrial metabolites acylcarnitines: therapeutic potential and drug targets. Bioenerg Commun 2022.15. https://doi.org/10.26124/bec:2022-0015

» Bioenerg Commun 2022.15. Open Access pdf
published online 2022-11-25 »Watch the presentation«

Dambrova Maija, Cecatto Cristiane, Vilskersts Reinis, Liepinsh Edgars (BEC 2022.15) Bioenerg Commun

Abstract: BEC.png https://doi.org/10.26124/bec:2022-0015

Dambrova 2022 graphical abstract.png

Acylcarnitines are esters of L-carnitine that emerge from the fatty acid metabolism pathways in mitochondria and peroxisomes.

Metabolomic profiling assays that investigate disease and nutrition states often include measurements of different acylcarnitines. This has resulted in increased interest regarding the consequences of increased or decreased plasma acylcarnitine concentrations and the mechanisms associated with these changes. An altered acylcarnitine metabolome is characteristic of specific inborn errors of fatty acid metabolism, and cardiovascular, metabolic, and neurological diseases in addition to some forms of cancer. Long-chain acylcarnitines accumulate under conditions of insufficient mitochondrial functionality reaching tissue levels that can affect enzyme and ion channel activities, and impact energy metabolism pathways and cellular homeostasis.

A better understanding of biochemical and molecular mechanisms behind the changes in acylcarnitine levels and their physiological and pathological roles forms the basis for future therapeutic target selection and preclinical drug discovery. This may explain off-target effects of some clinically used drugs and point to new indications for repurposing.
Keywords: acylcarnitine, mitochondrial physiology, energy metabolism, biomarkers, cardiometabolic diseases
Bioblast editor: Tindle-Solomon L O2k-Network Lab: AT Innsbruck Oroboros, LV Riga Liepins E

ORCID:ORCID.png Dambrova Maija, ORCID.png Cecatto Cristiane, ORCID.png Vilskersts Reinis, ORCID.png Liepinsh Edgars

Support

This work was part of the FAT4BRAIN project, with funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement nº 857394.


Preprint

» Dambrova 2022 MitoFit


Labels: MiParea: Exercise physiology;nutrition;life style, Pharmacology;toxicology 






FAT4BRAIN, BEC